EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors on Relationship Between B‐Type Natriuretic Peptide and Hemoglobin Levels in Patients With Cardiorenal Anemia Syndrome

Tomoaki Yoshitake, Toru Hashimoto iD, Shouji Matsushima iD, Kei Ikuta, Shoei Yamamoto iD, Tomoyasu Suenaga, Shunsuke Nakashima, Takashi Kai, Kayo Misumi iD, Keisuke Shinohara iD, Takeo Fujino iD, Shunsuke Katsuki iD und 3 weitere

Cardiovascular Therapeutics · 2025

DOI: 10.1155/cdr/3143864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Tomoaki Yoshitake und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Hemoglobins, Anemia, Cardio-Renal Syndrome, Natriuretic Peptide, Brain. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds Anemia is associated with poor prognosis in heart failure patients. Erythropoiesis‐stimulating agents have been used for the treatment of renal anemia, but they increase the risk of thrombotic events. Hypoxia‐inducible factor prolyl hydroxylase inhibitors (HIF‐PHIs) have emerged as a new treatment for renal anemia. HIF‐PHIs are expected to have pleiotropic effects beyond correcting anemia. Evidence regarding the effects of HIF‐PHIs in cardiorenal anemia syndrome has not been established. Methods and Results The present study is a single‐center, retrospective analysis of patients with heart failure and renal anemia who were treated with HIF‐PHIs or oral iron supplementation at Kyushu University Hospital ( n = 39 and n = 26). Both treatments significantly raised hemoglobin levels (HIF‐PHIs 9.1 [8.6–9.6] vs. 10.3 [9.5–11.8], p < 0.001; oral iron 10.1 [9.3–11.0] vs. 11.8 [10.6–13.2], p < 0.001). Log‐transformed BNP level (logBNP) decreased in the HIF‐PHI‐treated patients but not in those treated with oral iron despite the similar improvement in hemoglobin levels (HIF‐PHIs 2.74 [2.28–2.99] vs. 2.47 [2.16–2.66], p = 0.005; oral iron 2.38 [1.89–2.66] vs. 2.37 [1.90–2.50], p = 0.711). The levels of iron metabolism–related parameters after treatment were comparable between the two groups. Δ logBNP/ Δ Hb slope was significantly steeper in the HIF‐PHI group than the oral iron supplementation group (−0.100 vs. −0.047, p = 0.039), meaning that HIF‐PHIs further reduced BNP levels than anticipated by the increase of hemoglobin with conventional treatment. Conclusion HIF‐PHIs reduce BNP levels more than anticipated by the elevation of hemoglobin levels compared to oral iron supplementation. HIF‐PHIs may have therapeutic benefits against heart failure beyond the correction of anemia in the heart failure patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemoglobinsAnemiaCardio-Renal SyndromeNatriuretic Peptide, BrainHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsHeart FailureHematinicsHumansMaleFemaleRetrospective StudiesAgedBiomarkersMiddle AgedTreatment OutcomeJapanIronTime FactorsAged, 80 and over

Stichwörter der Autor:innen

anemiacardiorenal syndromechronic kidney diseaseheart failurehypoxia-inducible factor prolyl hydroxylase inhibitorsiron deficiency

Substanzen

HemoglobinsBiomarkersNatriuretic Peptide, BrainHypoxia-Inducible Factor-Proline DioxygenasesIronProlyl-Hydroxylase InhibitorsHematinics

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Advanced Cardiopulmonary Failure, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Toru Hashimoto, Shouji Matsushima, Shoei Yamamoto, Kayo Misumi, Keisuke Shinohara, Takeo Fujino, Shunsuke Katsuki, Kazuya Hosokawa, Shintaro Kinugawa, Kohtaro Abe

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yoshitake, T., Hashimoto, T., Matsushima, S., Ikuta, K., Yamamoto, S., Suenaga, T., Nakashima, S., Kai, T., Misumi, K., Shinohara, K., Fujino, T., Katsuki, S., Hosokawa, K., Kinugawa, S., & Abe, K. (2025). Effects of Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors on Relationship Between B‐Type Natriuretic Peptide and Hemoglobin Levels in Patients With Cardiorenal Anemia Syndrome. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/3143864

Vancouver

Yoshitake T, Hashimoto T, Matsushima S, Ikuta K, Yamamoto S, Suenaga T, et al. Effects of Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors on Relationship Between B‐Type Natriuretic Peptide and Hemoglobin Levels in Patients With Cardiorenal Anemia Syndrome. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/3143864

BibTeX
@article{Yoshitake2025,
  author = {Yoshitake, Tomoaki and Hashimoto, Toru and Matsushima, Shouji and Ikuta, Kei and Yamamoto, Shoei and Suenaga, Tomoyasu and Nakashima, Shunsuke and Kai, Takashi and Misumi, Kayo and Shinohara, Keisuke and Fujino, Takeo and Katsuki, Shunsuke and Hosokawa, Kazuya and Kinugawa, Shintaro and Abe, Kohtaro},
  title = {Effects of Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors on Relationship Between B‐Type Natriuretic Peptide and Hemoglobin Levels in Patients With Cardiorenal Anemia Syndrome},
  journal = {Cardiovascular Therapeutics},
  year = {2025},
  doi = {10.1155/cdr/3143864}
}
Kostenlos starten →